Fentanyl side effects: what 97,898 FDA adverse event reports show
Brand names
Fentanyl System
Who reports
97,898 reports · 85% serious · 27,747 with death outcome · 51% female
Used for
Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid-tolerant patients, that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
What it is
The system contains fentanyl, an opioid agonist, for transdermal administration. The amount of fentanyl released from each system per hour is proportional to the surface area (25 mcg/hour per 9.44 cm 2 ). The composition per unit area of all transdermal system sizes is identical.
Boxed warning
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM . WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM See full prescribing information for complete boxed warning. Fentanyl transdermal system exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,175 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Presbyacusis | 144 | 185.8 148.5–232.5ROR 186.1 · calibrated p 1e-9 ✓ | 97.9 EB05 85.2 · IC025 +5.9 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=144 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Vaginal flatulence | 125 | 148.5 118.2–186.8ROR 148.7 · calibrated p 8e-9 ✓ | 86.4 EB05 74.4 · IC025 +5.7 3/3 methods agree vs other Opioid Agonists: PRR 1.3 (1.0–1.5) | Not in label — unassessed | serious n=125 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Inspiratory capacity decreased | 99 | 120.4 94.0–154.1ROR 120.5 · calibrated p 4e-8 ✓ | 75.8 EB05 64.1 · IC025 +5.5 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=99 · ♀ 0% (drug 51%) · 100% clinician | no trial arm names this drug |
| Anaesthetic complication neurological | 309 | 110.0 95.9–126.2ROR 110.3 · calibrated p 6e-8 ✓ | 72.2 EB05 65.7 · IC025 +5.8 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=308 · ♀ 26% (drug 51%) · 100% clinician | no trial arm names this drug |
| Neuromuscular block prolonged | 110 | 90.0 72.0–112.5ROR 90.1 · calibrated p 3e-7 ✓ | 62.7 EB05 53.5 · IC025 +5.3 3/3 methods agree vs other Opioid Agonists: PRR 17.4 (10.7–28.3) | Not in label — unassessed | serious n=106 · 100% clinician | no trial arm names this drug |
| Myoglobin urine present | 64 | 73.6 55.3–97.8ROR 73.6 · calibrated p 2e-6 ✓ | 53.9 EB05 43.7 · IC025 +4.9 3/3 methods agree vs other Opioid Agonists: only this drug | Lab value / disease marker | serious n=63 · ♀ 100% (drug 51%) · 100% clinician | no trial arm names this drug |
| Maternal exposure during delivery | 239 | 69.8 60.3–80.8ROR 70.0 · calibrated p 2e-6 ✓ | 52.5 EB05 47.1 · IC025 +5.4 3/3 methods agree vs other Opioid Agonists: PRR 5.7 (4.6–7.1) | Reporting / coding artifact | serious n=194 · ♀ 100% (drug 51%) · 100% clinician | no trial arm names this drug |
| Victim of homicide | 134 | 66.5 54.7–80.7ROR 66.6 · calibrated p 3e-6 ✓ | 50.4 EB05 43.6 · IC025 +5.1 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=134 · ♀ 30% (drug 51%) · 100% consumer | no trial arm names this drug |
| Delayed recovery from anaesthesia | 204 | 58.6 50.2–68.4ROR 58.7 · calibrated p 5e-6 ✓ | 45.9 EB05 40.8 · IC025 +5.1 3/3 methods agree vs other Opioid Agonists: PRR 19.7 (13.5–28.8) | Not in label — unassessed | serious n=194 · 100% clinician | no trial arm names this drug |
| Counterfeit product administered | 247 | 51.4 44.7–59.0ROR 51.5 · calibrated p 1e-5 ✓ | 41.4 EB05 37.2 · IC025 +5.1 3/3 methods agree vs other Opioid Agonists: only this drug | Reporting / coding artifact | serious n=242 · ♀ 29% (drug 51%) · 100% consumer | no trial arm names this drug |
| Amnestic disorder | 87 | 47.4 37.6–59.8ROR 47.4 · calibrated p 2e-5 ✓ | 38.6 EB05 32.2 · IC025 +4.6 3/3 methods agree vs other Opioid Agonists: PRR 13.7 (8.4–22.6) | Not in label — unassessed | serious n=85 · ♀ 0% (drug 51%) · 100% clinician | no trial arm names this drug |
| Opiates positive | 86 | 46.1 36.5–58.3ROR 46.2 · calibrated p 3e-5 ✓ | 37.7 EB05 31.5 · IC025 +4.6 3/3 methods agree vs other Opioid Agonists: PRR 19.8 (11.1–35.6) | Lab value / disease marker | serious n=81 · ♀ 0% (drug 51%) · 100% clinician | no trial arm names this drug |
| Drug diversion | 982 | 44.2 41.3–47.4ROR 44.7 · calibrated p 3e-5 ✓ | 36.7 EB05 34.8 · IC025 +5.1 3/3 methods agree vs other Opioid Agonists: PRR 4.4 (4.0–4.8) | Reporting / coding artifact | serious n=446 · ♀ 23% (drug 51%) · 90% consumer | no trial arm names this drug |
| Pleural thickening | 112 | 42.0 34.3–51.4ROR 42.0 · calibrated p 5e-5 ✓ | 35.0 EB05 29.9 · IC025 +4.6 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=112 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Product counterfeit | 268 | 40.6 35.6–46.2ROR 40.7 · calibrated p 5e-5 ✓ | 34.1 EB05 30.8 · IC025 +4.8 3/3 methods agree vs other Opioid Agonists: PRR 25.9 (17.9–37.6) | Reporting / coding artifact | serious n=81 · ♀ 19% (drug 51%) · 100% consumer | no trial arm names this drug |
| Pleural fibrosis | 164 | 40.4 34.2–47.8ROR 40.5 · calibrated p 5e-5 ✓ | 34.0 EB05 29.8 · IC025 +4.7 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=164 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Intensive care unit acquired weakness | 60 | 39.8 30.2–52.5ROR 39.8 · calibrated p 7e-5 ✓ | 33.3 EB05 26.8 · IC025 +4.3 3/3 methods agree vs other Opioid Agonists: only this drug | Labeled (related wording) related wording | serious n=60 · ♀ 0% (drug 51%) · 100% clinician | no trial arm names this drug |
| Hyperthermia malignant | 225 | 38.4 33.3–44.2ROR 38.5 · calibrated p 7e-5 ✓ | 32.5 EB05 29.1 · IC025 +4.7 3/3 methods agree vs other Opioid Agonists: PRR 17.3 (12.3–24.3) | Labeled (related wording) related wording | serious n=219 · ♀ 27% (drug 51%) · 100% clinician | no trial arm names this drug |
| Procedural hypotension | 122 | 35.4 29.3–42.9ROR 35.5 · calibrated p 1e-4 ✓ | 30.3 EB05 26.1 · IC025 +4.5 3/3 methods agree vs other Opioid Agonists: PRR 13.6 (8.9–20.6) | Not in label — unassessed | serious n=117 · 100% clinician | no trial arm names this drug |
| Blood magnesium increased | 125 | 34.3 28.4–41.4ROR 34.3 · calibrated p 1e-4 ✓ | 29.5 EB05 25.4 · IC025 +4.4 3/3 methods agree vs other Opioid Agonists: only this drug | Lab value / disease marker | serious n=125 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Propofol infusion syndrome | 94 | 32.8 26.4–40.7ROR 32.8 · calibrated p 2e-4 ✓ | 28.4 EB05 23.9 · IC025 +4.3 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=94 · ♀ 0% (drug 51%) · 100% clinician | no trial arm names this drug |
| Drug abuse | 10,770 | 31.6 31.0–32.2ROR 35.3 · calibrated p 1e-4 ✓ | 27.6 EB05 27.1 · IC025 +4.8 3/3 methods agree vs other Opioid Agonists: PRR 3.9 (3.8–4.0) | Reporting / coding artifact | age-adj. PRR 28.0 · serious PRR 18.8 · ♀ 29% (drug 51%) · 91% clinician | no trial arm names this drug |
| Hypermobility syndrome | 60 | 29.4 22.5–38.5ROR 29.4 · calibrated p 4e-4 ✓ | 25.7 EB05 20.7 · IC025 +4.0 3/3 methods agree vs other Opioid Agonists: PRR 18.0 (9.2–35.2) | Not in label — unassessed | serious n=60 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Foetal exposure during delivery | 80 | 28.2 22.4–35.7ROR 28.3 · calibrated p 4e-4 ✓ | 24.9 EB05 20.6 · IC025 +4.1 3/3 methods agree vs other Opioid Agonists: PRR 24.0 (12.4–46.3) | Reporting / coding artifact | serious n=80 · 100% clinician | no trial arm names this drug |
| Bradycardia foetal | 89 | 26.0 20.9–32.4ROR 26.1 · calibrated p 6e-4 ✓ | 23.2 EB05 19.4 · IC025 +4.0 3/3 methods agree vs other Opioid Agonists: PRR 24.3 (13.0–45.4) | Not in label — unassessed | serious n=85 · 100% clinician | no trial arm names this drug |
| Prescription drug used without a prescription | 629 | 24.5 22.6–26.6ROR 24.7 · calibrated p 7e-4 ✓ | 22.1 EB05 20.6 · IC025 +4.3 3/3 methods agree vs other Opioid Agonists: PRR 28.2 (21.9–36.2) | Labeled (related wording) related wording | serious n=621 · 93% clinician | no trial arm names this drug |
| Homicide | 185 | 24.4 20.9–28.4ROR 24.4 · calibrated p 8e-4 ✓ | 21.9 EB05 19.4 · IC025 +4.1 3/3 methods agree vs other Opioid Agonists: PRR 11.3 (8.3–15.5) | Not in label — unassessed | serious n=77 · ♀ 27% (drug 51%) · 100% consumer | no trial arm names this drug |
| Local anaesthetic systemic toxicity | 105 | 24.1 19.7–29.4ROR 24.1 · calibrated p 9e-4 ✓ | 21.6 EB05 18.4 · IC025 +4.0 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=105 · 100% clinician | no trial arm names this drug |
| Female genital tract fistula | 153 | 20.8 17.6–24.6ROR 20.8 · calibrated p 0.002 ✓ | 19.0 EB05 16.6 · IC025 +3.9 3/3 methods agree vs other Opioid Agonists: PRR 1.3 (1.1–1.6) | Not in label — unassessed | serious n=152 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Accidental death | 148 | 18.5 15.7–21.9ROR 18.5 · calibrated p 0.003 ✓ | 17.1 EB05 14.9 · IC025 +3.7 3/3 methods agree vs other Opioid Agonists: PRR 2.2 (1.8–2.7) | Labeled (related wording) related wording | serious n=147 · 100% clinician | no trial arm names this drug |
| Inadequate analgesia | 657 | 17.7 16.3–19.2ROR 17.8 · calibrated p 0.003 ✓ | 16.4 EB05 15.4 · IC025 +3.9 3/3 methods agree vs other Opioid Agonists: PRR 4.0 (3.5–4.5) | Reporting / coding artifact | serious n=196 | no trial arm names this drug |
| Respiratory depression | 920 | 17.3 16.2–18.5ROR 17.5 · calibrated p 0.004 ✓ | 16.1 EB05 15.2 · IC025 +3.9 3/3 methods agree vs other Opioid Agonists: PRR 1.7 (1.5–1.8) | Labeled — boxed warning exact term | age-adj. PRR 13.9 · serious PRR 10.9 | no trial arm names this drug |
| Osteosclerosis | 115 | 16.8 13.9–20.3ROR 16.8 · calibrated p 0.005 ✓ | 15.6 EB05 13.3 · IC025 +3.6 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=115 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Anaesthetic complication | 192 | 16.5 14.3–19.1ROR 16.5 · calibrated p 0.005 ✓ | 15.4 EB05 13.6 · IC025 +3.7 3/3 methods agree vs other Opioid Agonists: PRR 12.3 (8.9–16.9) | Reporting / coding artifact | serious n=164 · 100% clinician | no trial arm names this drug |
| Bone cyst | 66 | 16.1 12.5–20.7ROR 16.1 · calibrated p 0.006 ✓ | 14.9 EB05 12.1 · IC025 +3.4 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=64 · ♀ 100% (drug 51%) · 100% clinician | no trial arm names this drug |
| Serotonin syndrome | 1,318 | 15.8 14.9–16.7ROR 16.0 · calibrated p 0.005 ✓ | 14.8 EB05 14.1 · IC025 +3.8 3/3 methods agree vs other Opioid Agonists: PRR 6.3 (5.8–7.0) | Labeled adverse reaction exact term | age-adj. PRR 13.5 · serious PRR 10.0 · 93% clinician | no trial arm names this drug |
| Drug specific antibody | 94 | 15.8 12.8–19.5ROR 15.8 · calibrated p 0.006 ✓ | 14.7 EB05 12.3 · IC025 +3.4 3/3 methods agree vs other Opioid Agonists: only this drug | Lab value / disease marker | serious n=94 · ♀ 100% (drug 51%) · 100% consumer | no trial arm names this drug |
| Radiculopathy | 179 | 15.5 13.3–18.1ROR 15.6 · calibrated p 0.006 ✓ | 14.5 EB05 12.8 · IC025 +3.6 3/3 methods agree vs other Opioid Agonists: PRR 1.4 (1.1–1.6) | Not in label — unassessed | serious n=178 · ♀ 100% (drug 51%) | no trial arm names this drug |
| Systemic infection | 111 | 15.2 12.6–18.5ROR 15.3 · calibrated p 0.007 ✓ | 14.2 EB05 12.1 · IC025 +3.4 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=111 · 100% clinician | no trial arm names this drug |
| Non-cardiogenic pulmonary oedema | 69 | 14.8 11.6–18.9ROR 14.8 · calibrated p 0.008 ✓ | 13.8 EB05 11.2 · IC025 +3.3 3/3 methods agree vs other Opioid Agonists: only this drug | Not in label — unassessed | serious n=68 · ♀ 0% (drug 51%) · 100% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Dependence / withdrawal | 8,577 | 6.46.2–6.5 | signal |
| Anaphylaxis / angioedema | 1,937 | 3.33.2–3.5 | signal |
| Kidney injury | 4,599 | 2.22.1–2.2 | signal |
| Rhabdomyolysis / myopathy | 801 | 2.12.0–2.3 | raised |
| Suicidality | 2,149 | 1.91.8–2.0 | raised |
| Arrhythmia / qt | 1,688 | 1.91.8–2.0 | raised |
| Anaemia | 2,411 | 1.71.7–1.8 | raised |
| Hyponatraemia | 594 | 1.61.5–1.7 | raised |
| Depression | 1,975 | 1.51.4–1.6 | raised |
| Thrombocytopenia | 1,543 | 1.51.4–1.6 | raised |
| Serious infection | 5,393 | 1.51.5–1.5 | raised |
| Gi bleeding | 1,244 | 1.51.4–1.5 | raised |
| Seizure | 1,330 | 1.51.4–1.5 | raised |
| Severe cutaneous reaction | 482 | 1.41.3–1.5 | raised |
| Extrapyramidal | 665 | 1.41.3–1.5 | raised |
| Neutropenia / agranulocytosis | 1,545 | 1.31.3–1.4 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug abuse | 10,770 | 31.6 31.0–32.2ROR 35.3 · calibrated p 1e-4 ✓ | 27.6 EB05 27.1 · IC025 +4.8 3/3 methods agree vs other Opioid Agonists: PRR 3.9 (3.8–4.0) | Reporting / coding artifact | age-adj. PRR 28.0 · serious PRR 18.8 · ♀ 29% (drug 51%) · 91% clinician | no trial arm names this drug |
| Pain | 7,311 | 2.6 2.5–2.6ROR 2.7 · calibrated p 0.736 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree vs other Opioid Agonists: PRR 0.8 (0.8–0.8) | Likely indication confounding term in indications; also in warnings | age-adj. PRR 1.7 · serious PRR 2.4 | no trial arm names this drug |
| Drug dependence | 6,096 | 8.3 8.1–8.5ROR 8.8 · calibrated p 0.050 ✓ | 8.0 EB05 7.9 · IC025 +3.0 3/3 methods agree vs other Opioid Agonists: PRR 0.5 (0.5–0.5) | Reporting / coding artifact | age-adj. PRR 8.0 · serious PRR 5.5 · 80% consumer | no trial arm names this drug |
| Toxicity to various agents | 6,041 | 8.0 7.8–8.2ROR 8.4 · calibrated p 0.057 | 7.7 EB05 7.5 · IC025 +2.9 3/3 methods agree vs other Opioid Agonists: PRR 1.0 (1.0–1.1) | Not in label — unassessed | age-adj. PRR 7.2 · serious PRR 5.3 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 5,826 | 0.9 0.9–1.0ROR 0.9 · calibrated p 0.271 | 0.9 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC vs other Opioid Agonists: PRR 1.6 (1.6–1.7) | Reporting / coding artifact | age-adj. PRR 1.0 · serious PRR 1.2 | no trial arm names this drug |
| Overdose | 5,826 | 5.9 5.7–6.0ROR 6.2 · calibrated p 0.137 | 5.8 EB05 5.6 · IC025 +2.5 3/3 methods agree vs other Opioid Agonists: PRR 0.6 (0.6–0.6) | Reporting / coding artifact | age-adj. PRR 4.5 · serious PRR 4.8 | no trial arm names this drug |
| Death | 5,472 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.565 | 1.4 EB05 1.3 · IC025 +0.4 vs other Opioid Agonists: PRR 0.7 (0.7–0.7) | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 1.5 · serious PRR 0.9 | no trial arm names this drug |
| Nausea | 5,170 | 1.4 1.4–1.4ROR 1.4 · calibrated p 0.594 | 1.4 EB05 1.4 · IC025 +0.4 vs other Opioid Agonists: PRR 1.3 (1.3–1.3) | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.5 | no trial arm names this drug |
| Vomiting | 3,775 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.806 | 1.7 EB05 1.7 · IC025 +0.7 vs other Opioid Agonists: PRR 1.3 (1.2–1.3) | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.5 | no trial arm names this drug |
| Fatigue (tiredness) | 3,577 | 1.0 1.0–1.0ROR 1.0 · calibrated p 0.297 | 1.0 EB05 1.0 · IC025 -0.1 PRR-only: not supported by EBGM or IC vs other Opioid Agonists: PRR 1.3 (1.2–1.3) | Labeled adverse reaction exact term | age-adj. PRR 0.9 · serious PRR 1.0 | no trial arm names this drug |
| Off label use (used outside approved label) | 3,440 | 0.8 0.8–0.9ROR 0.8 · calibrated p 0.208 | 0.8 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC vs other Opioid Agonists: PRR 1.3 (1.3–1.4) | Reporting / coding artifact | age-adj. PRR 0.8 · serious PRR 0.9 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 3,026 | 1.1 1.1–1.2ROR 1.2 · calibrated p 0.407 | 1.1 EB05 1.1 · IC025 +0.1 vs other Opioid Agonists: PRR 1.3 (1.3–1.4) | Labeled adverse reaction exact term | age-adj. PRR 1.1 · serious PRR 1.0 | no trial arm names this drug |
| Drug withdrawal syndrome | 3,022 | 7.5 7.3–7.8ROR 7.7 · calibrated p 0.074 | 7.3 EB05 7.1 · IC025 +2.8 3/3 methods agree vs other Opioid Agonists: PRR 0.6 (0.6–0.6) | Labeled adverse reaction exact term | age-adj. PRR 6.5 · serious PRR 5.7 | no trial arm names this drug |
| Hypotension (low blood pressure) | 3,005 | 3.2 3.1–3.4ROR 3.3 · calibrated p 0.532 | 3.2 EB05 3.1 · IC025 +1.6 3/3 methods agree vs other Opioid Agonists: PRR 2.0 (1.9–2.1) | Labeled adverse reaction exact term | age-adj. PRR 3.2 · serious PRR 2.5 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 2,993 | 1.0 1.0–1.0ROR 1.0 · calibrated p 0.304 | 1.0 EB05 1.0 · IC025 -0.1 PRR-only: not supported by EBGM or IC vs other Opioid Agonists: PRR 1.3 (1.2–1.4) | Labeled adverse reaction exact term | age-adj. PRR 0.9 · serious PRR 1.0 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Presbyacusis — n=144, PRR 185.8
- Vaginal flatulence — n=125, PRR 148.5
- Inspiratory capacity decreased — n=99, PRR 120.4
- Anaesthetic complication neurological — n=309, PRR 110.0
- Neuromuscular block prolonged — n=110, PRR 90.0
- Victim of homicide — n=134, PRR 66.5
- Delayed recovery from anaesthesia — n=204, PRR 58.6
- Amnestic disorder — n=87, PRR 47.4
- Pleural thickening — n=112, PRR 42.0
- Pleural fibrosis — n=164, PRR 40.4
✓ A hand-written Bradford Hill causality assessment exists for this drug: Fentanyl (opioids) ↔ Respiratory depression.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Fentanyl?
In FDA FAERS, the most frequently co-reported reaction terms for Fentanyl are pain, toxicity to various agents, nausea, vomiting, fatigue, dyspnoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Fentanyl have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM . WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM See full prescribing information for complete boxed warning. Fentanyl transdermal system exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death.
Do FAERS signals prove that Fentanyl causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 242759ef-cb6d-4e3e-9f8d-5e31efa1f289, effective 20260302; matched on
openfda.generic_name.exact:"FENTANYL" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,215 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
FENTANYL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.